Kareminju

Adult dosage

Administer intravenously as a drip with a maximum dosage of 1–1.5 g per kg of body weight per day as total amino acids. The infusion rate should ideally yield a concentration of about 10 g total amino acids over 60 minutes, adhering to a principle of drip administration of 80–130 drops per minute. The maximum daily dosage is 100 g of D-sorbitol.

Children's dosage

In children, dosage and infusion speed should be adjusted accordingly.

This drug should be used strictly under the supervision of a doctor and should not be taken or used independently. Do not administer this drug to patients with hepatic coma or at risk, those with severe renal impairment, or those with certain metabolic disorders. It should also be avoided in patients with severe heart failure, pulmonary edema, oliguria or anuria, and electrolyte imbalances such as hypernatremia. In cases of lactic acidosis or methanol poisoning, as well as those with hereditary fructose intolerance, administration is contraindicated based on the ingredients of this drug. Caution is also needed for patients with heart-related diseases, atrioventricular block, and severe myasthenia gravis. This drug should be administered carefully to patients with impaired liver or kidney function, severe acidosis, or congestive heart failure, and those with abnormalities in sodium or potassium levels. Contains sodium bisulfite, which can cause allergic reactions or asthma attacks, so patients with asthma should be particularly cautious. During use, side effects such as skin rash, nausea, vomiting, palpitations, and elevated blood pressure may occur, and in severe cases, breathing difficulties or shock may also arise. Rapid large doses can cause acidosis, so care should be taken with the administration speed and amount. Additionally, patients with impaired liver or kidney function may show abnormalities in blood tests, necessitating regular checks. When using this drug, care must be taken to maintain electrolyte balance, especially when used in conjunction with other electrolyte solutions. Safety has not been fully established for pregnant women, so it should only be used when the benefits of treatment outweigh the risks. In children, liver function may be immature, requiring lower dosages, and blood ammonia levels should be frequently monitored. In the elderly, physical functions are often diminished, so it is necessary to slow the administration speed and adjust the dosing. This medication should be administered slowly intravenously, as rapid administration can cause chills or vomiting. Before use, ensure the solution is clear and without abnormalities, and do not use if it is contaminated or discolored. Preparation and management of the injection device must be done in a sterile manner, and it should be stored in a sealed container at a proper temperature without opening the packaging.

Serious side effects

Difficulty breathing, respiratory arrest, shock, bronchospasm, asthmatic attack, elevated blood pressure (including severe edema or urinary abnormalities)

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• tachycardia
• elevated blood pressure
• acidosis
• heat sensation
• vascular pain

This drug should be stored in a sealed container to prevent air and moisture from entering. The storage temperature should ideally be maintained between 1 and 30 degrees Celsius.

Appearance

A colorless to pale yellow transparent solution contained in a colorless, transparent glass bottle with a rubber stopper for infusion.

Package unit

250mL/bottle x 1